# US 2021/0341487 A1 · Neutralizing antibody assay for therapeutic proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341487 A1
- Document ID: US20210341487A1
- Status: Published application
- Kind: A1
- Application number: 17/245,271
- Filed: 2021-04-30
- Published: 2021-11-04
- Earliest claimed: 2020-05-01
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Michael Partridge; Susan Irvin; Manoj Rajadhyaksha; Aynur Hermann
- Web page: https://patentgrep.com/patent/US20210341487A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/5023: {on expression patterns}
- G01N 33/5041: {involving analysis of members of signalling pathways}
- G01N 33/6854: {Immunoglobulins}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention generally pertains to methods of testing for the presence of neutralizing antibodies (NAbs) against therapeutic proteins. In particular, the present invention pertains to the use of mitigating agents against interfering competing drugs in ligand binding assays or cell-based assays for the detection of neutralizing antibodies against therapeutic proteins.

## Claims

### Claim 1

A method for detecting a neutralizing agent to a therapeutic protein in a sample, comprising:
(a) contacting said sample having said neutralizing agent and a competing drug to said therapeutic protein, a target of said therapeutic protein, and a mitigating agent;
(b) measuring a binding of said therapeutic protein to said target; and
(c) comparing the result of (b) to a control measurement to detect said neutralizing agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein said control measurement includes measuring binding of said therapeutic protein to said target in the absence of a neutralizing agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein said neutralizing agent is a neutralizing antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein said therapeutic protein is selected from a group consisting of an antibody, a soluble receptor, an antibody-drug conjugate, and an enzyme.

### Claim 5 (depends on 1)

The method of claim 1, wherein said therapeutic protein is a monoclonal antibody.

### Claim 6 (depends on 5)

The method of claim 5, wherein said monoclonal antibody is selected from a group consisting of an anti-PD-1 antibody, an anti-TNF antibody, an anti-PD-L1 antibody, an anti-EGFR antibody, an anti-CD20 antibody, an anti-CD38 antibody, and an anti-LAG3 antibody.

### Claim 7 (depends on 1)

The method of claim 1, wherein said therapeutic protein is a bispecific antibody.

### Claim 8 (depends on 7)

The method of claim 7, wherein said bispecific antibody is selected from a group consisting of a CD20×CD3 antibody, a BCMA×CD3 antibody, a EGFR×CD28 antibody, and a CD38×CD28 antibody.

### Claim 9 (depends on 1)

The method of claim 1, wherein said therapeutic protein is immobilized to a solid support.

### Claim 10 (depends on 1)

The method of claim 1, wherein said therapeutic protein is labeled for detection.

### Claim 11 (depends on 10)

The method of claim 10, wherein said label is detectable by fluorescence, chemiluminescence, electrochemiluminescence, radioactivity, or affinity purification.

### Claim 12 (depends on 11)

The method of claim 11, where said label comprises ruthenium.

### Claim 13 (depends on 1)

The method of claim 1, wherein said target is an antigen, a receptor, a ligand, or an enzymatic substrate.

### Claim 14 (depends on 1)

The method of claim 1, wherein said target is a cell surface protein.

### Claim 15 (depends on 1)

The method of claim 1, wherein said target is a recombinant protein.

### Claim 16 (depends on 1)

The method of claim 1, wherein said target is expressed by a cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein said cell is a HEK293 cell, a MOLP-8 cell, a Jurkat cell, or a modified version thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein said target is immobilized to a solid support.

### Claim 19 (depends on 1)

The method of claim 1, wherein said target is labeled for detection.

### Claim 20 (depends on 19)

The method of claim 19, wherein said label is detectable by fluorescence, chemiluminescence, electrochemiluminescence, radioactivity, or affinity purification.

### Claim 21 (depends on 1)

The method of claim 1, wherein said target is an enzymatic substrate.

### Claim 22 (depends on 1)

The method of claim 1, wherein said target is CD20, CD3, BCMA, PD-1, EGFR, CD28, CD38, TNF, PD-L1, or LAG3.

### Claim 23 (depends on 1)

The method of claim 1, additionally comprising a second target.

### Claim 24 (depends on 1)

The method of claim 1, wherein said competing drug is a monoclonal antibody.

### Claim 25 (depends on 24)

The method of claim 24, wherein said competing drug is rituximab, pembrolizumab, nivolumab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, ublituximab, cetuximab, daratumumab, or adalimumab.

### Claim 26 (depends on 1)

The method of claim 1, wherein said competing drug is a bispecific antibody.

### Claim 27 (depends on 1)

The method of claim 1, wherein said mitigating agent is a monoclonal antibody.

### Claim 28 (depends on 1)

The method of claim 1, comprising using two, three, four or more mitigating agents.

### Claim 29 (depends on 1)

The method of claim 1, wherein a binding of said therapeutic protein to said target is measured by measuring receptor phosphorylation, phosphorylation of downstream proteins in a signal transduction pathway, cytokine release, cell proliferation, cell death, or production of a secondary protein.

### Claim 30 (depends on 1)

The method of claim 1, wherein a binding of said therapeutic protein to said target is measured by the expression of a reporter gene.

### Claim 31 (depends on 30)

The method of claim 30, wherein said reporter gene is luciferase.

### Claim 32 (depends on 1)

The method of claim 1, further comprising a pre-treatment step of contacting said sample to said mitigating agent prior to contacting said sample to said therapeutic protein or said target.

### Claim 33

A kit, comprising:
(a) a therapeutic protein;
(b) a target of said therapeutic protein;
(c) a neutralizing agent against said therapeutic protein;
(d) a competing drug; and
(e) a mitigating agent.

### Claim 34 (depends on 33)

The kit of claim 33, further comprising cells that express said target.

### Claim 35 (depends on 34)

The kit of claim 34, further comprising cells that produce a measurable activity or signal in response to the binding of said therapeutic protein to said target.

### Claim 36 (depends on 35)

The kit of claim 35, wherein said activity is the expression of luciferase.

### Claim 37 (depends on 33)

The kit of claim 33, wherein said target is immobilized to a solid support.

### Claim 38 (depends on 33)

The kit of claim 33, further comprising a label affixed to said therapeutic protein.

### Claim 39 (depends on 38)

The kit of claim 38, wherein said label comprises ruthenium.
